-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DdUIM4a1XcFo+SzjIX5Gr8v0EnzCnjBmRHRiX5iWb1m7zM/1WI756e7uH+JKAxxv
 WHdSdUskppB3xjjDM4exFw==

<SEC-DOCUMENT>0000950123-09-055657.txt : 20091030
<SEC-HEADER>0000950123-09-055657.hdr.sgml : 20091030
<ACCEPTANCE-DATETIME>20091030162349
ACCESSION NUMBER:		0000950123-09-055657
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20091027
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091030
DATE AS OF CHANGE:		20091030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		091148461

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c91699e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): October 27, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, New Jersey<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;3.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer or Listing.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt; text-indent: 4%">On October&nbsp;27, 2009, Cyclacel Pharmaceuticals, Inc. (the &#147;<U><B>Company</B></U>&#148;) received a deficiency letter from The
NASDAQ Stock Market LLC (&#147;<U><B>NASDAQ</B></U>&#148;) notifying the Company that for the last 30 consecutive business days the bid
price of the Company&#146;s securities had closed below $1.00 per share, the minimum closing bid price required by the
continued listing requirements of NASDAQ set forth in NASDAQ Marketplace Rule&nbsp;5450(a)(1) (the &#147;<U><B>Rule</B></U>&#148;).


<P align="left" style="font-size: 10pt; text-indent: 4%">In accordance with Marketplace Rule&nbsp;5810(c)(3)(A), the Company has been given a grace period of 180 calendar days,
or until April&nbsp;26, 2010, to regain compliance with the Rule. To regain compliance, the closing bid price of the
Company&#146;s securities must meet or exceed $1.00 per share for at least ten consecutive business days. If the Company
does not regain compliance with the Rule by April&nbsp;26, 2010, NASDAQ will provide written notification to the Company
indicating that its securities may be delisted from The NASDAQ Global Market. Alternatively, the Company may be
eligible for an additional grace period if it meets the initial listing standards, with the exception of bid price, for
The NASDAQ Capital Market.




<P align="left" style="font-size: 10pt; text-indent: 4%">On October&nbsp;30, 2009, the Company issued a press release announcing its receipt of NASDAQ&#146;s deficiency letter. A
copy of the press release is being furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>

</TABLE>



<P align="left" style="margin-left:4%; font-size: 10pt">(d)&nbsp;Exhibits:



<P align="left" style="margin-left:4%; font-size: 10pt">The following exhibit is furnished herewith:



<P align="left" style="margin-left:4%; font-size: 10pt">99.1 &nbsp;&nbsp;Press release, dated October&nbsp;30, 2009

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.



<P align="left" style="margin-left:46%; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>



<P align="left" style="margin-left:46%; font-size: 10pt">By: <U>/s/ Paul McBarron&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name: Paul McBarron<BR>
Title: Executive Vice President &#151; Finance,<BR>
Chief Financial Officer and Chief<BR>
Operating Officer<BR>


<P align="left" style="font-size: 10pt">Date: October&nbsp;30, 2009

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release, dated October&nbsp;30, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c91699exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<P><DIV style="position: relative; float: left; width: 48%">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c91699p9169901.jpg" alt="(LOGO)">

</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 48%">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Cyclacel Pharmaceuticals, Inc.
</DIV>

</DIV>
<BR clear="all"><BR>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c91699p9169902.jpg" alt="(PRESS RELEASE)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS RECEIVES DEFICIENCY NOTICE FROM<BR>
NASDAQ GLOBAL SELECT MARKET</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Berkeley Heights, NJ, October&nbsp;30, 2009 </B>&#151; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;) announced today that it received a Nasdaq Staff Deficiency
Letter on October&nbsp;27, 2009 indicating that the Company fails to comply with the minimum bid price
requirement for continued listing set forth in Marketplace Rule&nbsp;5450(a)(1). The letter gives
Cyclacel notice that the Company&#146;s bid price of its common stock has closed under $1.00 for the
last 30 business days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Nasdaq notice has no effect on the listing of the Company&#146;s common stock at this time. Pursuant
to Nasdaq Marketplace Rule&nbsp;5810(c)(3)(A), the Company has an initial period of 180 calendar days,
or until April&nbsp;26, 2010, to regain compliance. The letter states the Nasdaq staff will provide
written notification that the Company has achieved compliance with Rule&nbsp;5450(a)(1) if at any time
before April&nbsp;26, 2010, the bid price of the Company&#146;s common stock closes at $1.00 per share or
more for a minimum of 10 consecutive business days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If the Company cannot demonstrate compliance with Rule&nbsp;5450(a)(1) by April&nbsp;26, 2010, it may
transfer its listing to The Nasdaq Capital Market if it meets the initial listing criteria set
forth in Nasdaq Marketplace Rule&nbsp;5505, except for the bid price requirement. In that case, it may
have an additional 180 calendar day compliance period in which to comply with the minimum bid price
requirement. The Company currently meets these initial listing criteria. Otherwise, the Nasdaq
staff may begin the process to have the Company&#146;s securities delisted. At that time, the Company
may appeal the Nasdaq staff&#146;s determination to delist its securities to a Listing Qualifications
Panel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and
commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious
disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the
treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and
in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor,
is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and
VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals
subsidiary markets directly in the U.S. Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis, Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid
and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial
products and a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U>
for additional information.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT face="Wingdings">&#254;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">200&nbsp;Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ 07922 USA&nbsp;T:&nbsp;&#043;1&nbsp;(908)&nbsp;517&nbsp;7330 F:&nbsp;&#043;1&nbsp;(866)&nbsp;271 3466</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel &#043;44&nbsp;1382&nbsp;206&nbsp;062&nbsp;Fax &#043;44&nbsp;1382&nbsp;206&nbsp;067</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt"><U>www.cyclacel.com</U> &#151; <U>info@cyclacel.com</U></DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risk factors</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended
utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk
that product candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel
will not obtain approval to market its products, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated with reliance on collaborative
partners for further clinical trials, development and commercialization of product candidates. You
are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable
words to be uncertain and forward-looking. These factors and others are more fully discussed under
&#147;Risk Factors&#148; in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2008, as
supplemented by the interim quarterly reports, filed with the SEC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investors/Media:<BR>
Corey Sohmer, (908)&nbsp;517-7330<BR>
<U>csohmer@cyclacel.com</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> Copyright 2009 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and
Cyclacel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks
of Sinclair Pharma plc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c91699p9169901.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c91699p9169901.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%<`PP,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`/+?$?QL^$GA&1X->^(7A>RN8]WF6<6IPW]]&5
MQE7L=-^T3J_S`[#'N(.0,5]!@>$^),PBI8/)<74IO:;I2IT]>JJ5>2%O/FL?
M+YCQKPEE$I0QW$&"H5(;TXUHU:D;='2H^TJ)Z[.-WV.+@_:M^`%Q,EO'\0K>
M-V;:K7.@>++*W!)QE[J[T&*"-<_Q-(H[YQ7K3\.N,Z<'-Y)*R5[0Q&#G+Y0A
MB)3;\E&YXE/Q6\/YSC3CQ#"+;LG/"8^E#YSJ86,$O-R2\SUCPSX^\$>,DW^%
M/%GA[Q!A2[1:5JUE=W$:C.6EM8IC-"/E/WXUZ9KYO'Y-FV5.V8Y;B<#K9.K1
MG3BV_P"6;BHO?HV?6Y9GV29NKY3FV$Q]M7&A7ISG&V_-3C+GCL_BBCKJ\T]8
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/-?BC\5?"7PC\-R>
M(?%%TRF1G@TC2+7;)JFM7RIO%I80%@,`;3+/(5BA5@TC#<H?W>'N'<RXCQT<
M%EU.RC:5:M*ZI8>FW;GJ27SY8*\YO2*=FU\WQ1Q5E/".6RS#-*KCS7C0P\+.
MOB:J5_9THMKR<YRM""=Y.[BG^;FI>-?VBOVI=3O-/\)V-_I'@Y)C%)I^EW<F
MC^&K*/KY>O>(W$;ZQ>;/F>W0N"<F.T45^ZX?*>"/#S#TJV8U:>(S.UU4JP5;
M%3??#X9<RH0OHINW]ZLV?S=B<Z\1/%+$UL/E-"K@LF4N5TJ,WA\'3C;;%8M\
MKQ%2VLJ:OKK"@D<U=?!'X1>"6:U^(OQZT>/5X&476@>`-#N?$<\+[7,D$E^A
M=(9PR@?OK>+!.&49!/?3XLXES-*>1<'5OJTK\F(S&O'"Q:NK25-\KE%IW]R<
MKK9L\RKP1PADC=+B+CS#PQ=.RGA<JPT\9*+LVX.JKJ,E9+WZ<;/1I:&&WAG]
MF2[=+>S^*GQ)T9R0&OM8\"6VH628SN)ATUHIP&/(P&([YS74L?Q]13E4X=RS
M$I;4Z&/E2G_X%54H>NUSB>5^&-5QIT>*<WP3ZU,1EL*M-=_<H2C45^EKVZD+
M_`SQ$8W\1_"+QGX?^)L6F#[47\$ZC<:3XVTQ$VD7$GAF[>'48B&(Q]F>9S@X
M7((6UQ=@8M8'B3*L1D$J_N)8ZG&K@:K=_=6*@I4'?K[11CYZJ\/@7,5&68\(
M9UA>)887]Y?+:LZ&944OMRP51PQ,7KI[)SD^BT=O9?@U^V+XF\)W</AKXL&\
M\0:%%+]C;7Y867Q1H+K)L<ZK$55M8MHCN\WS%6\0`G=,5$9^6XH\,,!CZ4L=
MPVH8'%M<ZPRE_LF(35U[%W:HRE]GE;HRVM"_,?9<&>,69Y56AEG%?M,?@H2]
MF\4XOZ[AFG9^V5D\1"#^/F2KQU?-4:4'^I-M<07EO;W=K*D]M=0Q7%O-&<QS
M03HLL,J'NC1LK`^A%?S[.$Z4YTJD7"I3DXRB]'&479I^::LS^HZ=2%:G3JTI
M*=*K&,X26JE&24HR3[--->1-4%A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0!C^(->TOPMH>K>(M:N5L])T33[K4K^X;'[JVM(FFD*KD;Y&"[40<LS*HY
M85TX+!XC'XO#8'"4W4Q&*J0I4X+K.;27HE>[>R2;>B./,,=A<KP.+S#&5%1P
MF!I3K59/[,(1<I6763M:,5K*326K/S$\+^&]4_:B\<>(OB[\3;V;P[\)?"AN
M$1);@VD$6EZ?NNQX?LKG($"16Q%QJE_'AVDG\N(JS+]G_?L?CL/X>Y3@>&L@
MI1QG$F8<K;4>:3JU/<^L3C]IRE[F$HOW5&/-*Z3Y_P"8\LRW%>*&=YCQ=Q-6
MEEO"65<R2E/V<50I?O/JM.>BBHP_>8RO'WG*?+"SDO9ZFI^)/&?QS@O_``S\
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M)/XI_8P^QZ/Y:S2WGAV^\9Z=?64)D`,C7]G-?+"X4XV3Q(,D;QCBN?#8FE6J
M1AEWBG[3$W<8PQ-/`U*<W;94YJBY)O6\)-VV=]3JQ>#K8:E*>:^#/LL&DI2J
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MVVV?OE*E3HTZ=&E!4Z5*,80BM%&,4HQBO)))(_8:H+"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@#XQ_;)UG5KW0?`GPH\/L1JOQ-\5VUC(B,<M8:=/9[
M8ID4Y^S/JE_I\KDC!2QDR<`U^I>%^%PU#&9OQ%C%;#</X251-]*E6,[N/]Y4
MJ=2*MK>I'K8_&?&/&8NM@,BX4R]VQ7$V.A3:7_/JC*G:,DMH2KU:4V]K4Y=+
MG._%KPR?+^$G[)7@"=]-L-5M8]7\9ZA!M6>/PQI,KS75Y=`'#SW^HPZA>.K\
M27$-O'RDI%=O#>/M+B3Q(SB"K5L--T<#3E\+Q59)1A#M&C2E3I)K6-.4Y;QN
M>?Q9EGN\)^$V03>&P^*A&OF-6%E)8.A)RG4FMG*O5A6K23LI5HTH?#.QR_B*
MR\*^+1K6DWES<>%_V7_@-*FBSV&D,T-W\1_&]FR1S6,4D!5]0<:A,L(=3YDM
MQ=>8KB2[,MKZ&!JYCE?U7$TJ<<?X@<8)UXU*R3AEF`FFU4:EI27LTY6?NPIP
MY6G&GR5/-S##Y7FJQF#JU)97X8\"26&E2H/DJ9MF5-I2IJ4;.K)U9*'-?FG4
MJ>T4E.LZE&34+SQ-<0Z5HFKZWX@^$6AWML+KPC\!?@;H0O\`XE2:%(%6+5/%
M5[9QJ-)FF15:3[28XF8LK#SED!5"E@*<L1BL+A,/Q)BZ4^3&<09]B/996L0K
MMTL)3FW[:,7=1]G>:5FGR.(\35S*<,-@<5C<5PE@:\.?`<,<-8;VF<O"OE4:
M^,J4U'V$IKX_:VA*[4HQJ*9R-[X<MO!I745\1_M4_!R7,2Q>+?%\</B;PC&T
MH9X_[>_X1Z[9[*%Y1'YBR[U0;MZ=:]*CCIYBG0^H\)<3Q5V\'@W+"8QI63^K
M_68)3DE?E<>5R=N66QY5;+J>3N.(68\;<'SM%1QV/C'%X!.5W%8KZG-2@I2Y
M>:,N=)-WB]3K]/\``FD>)]1T?7/CVW@_0]9M_$7AN'X>?%CPGXL\.^&+'XW:
MIJ,DU]HNA);R%%U/6[C[&ACFMX+:[8.R(`8RS_/9IQ31X<PTL)PWBZJP^.A7
MH8G)LSHU:E3*JG+R2]E.<ERI\TDJ+G5IW7,TT[+Z?)N"ZW%.+AC>*\#0^M9;
M4P^(PF?916HTJ6<TG+VD76ITXM2DE&+]O&G1JI/E3BTI2\MU3]GWQ9_P4-TO
MPAXV_:-\#?$#]F/Q#\'OB'K^F:)X9T[4DNG\7^$+D:!?SWT3ZC9P2Z/J/V^P
M^RP:S:+-$ZVTDT"2I)$;?\@/W7\#]9%4*JJ,X4!1DDG`&!DGDGWH`6@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@#PSQ_\<M(\`>(X_#UUHNJ7\C6<MT9[.*21"UK
M;1:C>PLR1-':+'I4OGQ37#QK<SH;.(>:=P`/<Z`"@`H`^/\`QO:C6OVQ/A/I
M]T@DL_#GPXUCQ/:IA/DO[F\\0V'F/N!^56M+)UQR'C!&.M?IN4U/J?ACQ'6I
M/DJ8W,Z.%D]5^[C##5+*W5J=1/HTVC\@SNE]=\8>%,-57-1RW**^-A'32K.I
MC*7,[]$X4VK:J235MRO;W_V3XN?M3?$1D?[9\/?A_H>B:21DO'%'X5N_$UTU
MN[96)I+NRMR5`Z\G[QW7.AS\->'N21:]EG68UZ];HFWBX86/,E9NT*DM?ET5
MHIXCV/%GBCQ`XVK</95A\/0?6,?J,\9/E;TC>I2B[);N_5WQ]%\.V?A[PS\%
MM"O84N]#\"_#?Q!\=?$-HS,L7B#Q?;6VG2Z6]VWED3>5J_B'4[Q"Y.'MK<D,
M(@*Z<5C:N,Q_%6+I2=+%YMF>&R##32UPV#G*HJO(KKEYJ.&I4W:WNSGJG(X\
M'E]'+\MX,P-:FJF`R+)\7Q/BZ;;Y<3CX0I2H<[:;ER5\76JQO?6%.Z:C8^E?
MAAX*C\*Z(=2U)4N_&WBLQZ]XWUR50UYJ&MWL2RR6:RDDQ:1IRLMC96B$10V]
MJ@5=[NS_``F?YJ\?BUA\.W2RG+KX?`8>.D*="#:4^71.M7:=:O4:YYU)N[LH
MI?I/#&2QRK!/$XE*KG6:VQ698EJ]2KB:B4I4U+5QP^'35##4HM0ITH1LN9R;
MZKQ-JD&F::87L/[5N]6^U:5I6CO#.UKJ^IR:;?WD&EWUW'97,.EV5U'931/>
M7J+;)O57):1(Y/#A.5.49TY.G.FU*,HMQE%IW335FFGJFM4SZ.<(5(2I5(1J
M4ZB<90DE*,HR5G&47=---IIJS6C/)=&^#NG>()--U?XD:)HE_I-A+\.O%W@/
MX2:AH/A/4?#WP*\;^%]'N8]1N/!NO:;H]K/JM[)JFH2O]NF`6-K,&S2&*9DJ
MZ]>MB:M2OB*TZ]>JW*=2I*4YSD]Y2E)N4F^[=S/#X;#X.A2PN$H4\-AJ$5&G
M2I0C3IPBMHPA!*,5Y))'O=9&Q1U34K'1=,U'6-4N8K+3-)L;O4M1O)VV0VEC
M86\EU=W,S'[L45O%(['L$)H`_,WX5Z[^TQ^VW87_`,5]'^+>I?LV?L_7NM:Q
MI?PUT#P-X=T+4OB3XWT;1M3FTN?Q7XA\3^([2Y7P\LUU:7D,5K80$"2*571T
MMX[B^`/1_B5\&OVH_!OP/\:?\*V_:3\=>/\`XE>%=7LO'/P]/B+P[X2MM1UC
M3=#MYGUCX9^()-*TV*'Q/;:Q!O>WN)H+:=;V.WB\U+>1P`"EXI_;?TO4/V2_
M"WQD^&^G_P!I?%/XK2V/PX^'/P[0+<ZG'\;-6D;1[KP[=64A5WM]#U-+N]F:
M81+-:VMN2T?V^$D`YCQM\3OCY\'M'_9\_95\%^*K/XF?M6?%O3[_`%?Q3\2/
M'B1W7A[P3HE@LU_XK\5RZ7IUO:K=Z?93"]L='M#"!+%HCM.D]RXBN`#U70/V
M:OV@=(U/1?$6H_MM?%77-;M-5T^^UW3KOP/\.H?`^N:?!<13:CHL'A6'20VB
MQ7D0N;<75O?-+`DZO&/,A5J`*WPJ^)/CK6OVXOVI?AKJOB2^O?`O@GP/\(-2
M\*>&I5MA8:)?:_H<5SK%S:-'`LQDNKAG=_,E<9;`````!]P$A02Q"A0223@`
M#DDD]`!0!^,7A_\`:G^-,GQV\._M`ZCXQG/['_Q#_:%\0_LW>'?"OV*S_LRS
ML[+1X=%\+_$Z/4DMC*EEJOC;3]4E>22<&)+6\B;Y&B50-O(_0?\`:N_:$3]F
M[X4OXQL-`?Q=XS\0^(=&\!_#?PA&[1?\))X[\2O,FCV$[QL)%LTBMKNZE$1$
MDBVGDQLDDRNH!XYHO[.?[5_BK3+?Q%\3?VR_&GA7QO=VR7?_``C'PG\&^!=+
M\`>%+V;]X=)2#5M(N[OQ=96P8Q&>]FADE9=Q8J%)`/,/VD]6^.]A\</V*?V?
M]$^/OBWPK<?$;P_\1-.^(GCSPKX?\,V.H^*-8\'>&M)U*+Q"=!NK&YL=,EN;
MNWNW:UMBL,*ZC*$!$:8`V/J7X?\`PB^)GPGM?&^O>*?VCOB/\7XY_"&I0Z7I
M?C'2O"MA::'J-K')>QZQ9/H>F6\DEYMB\G;*6CVR,2I(7:`>>_\`!.7XE^._
MBW^RCX'\<_$CQ)?>+/%FI:UXVMK[6]16V2[N(--\6:K86,<BV<$,6(;2"*,$
M1@D(,DGF@#[/OM`T74;F.\O]+LKNYB2*)9IX$=FB@N%NX(9LC$\,5VJSQQRA
MU251(@#C=0!KT`%`!0!\Q^-;2/2/VH/@[XAE'EQ^)?!?C;P<)CDJUWI2'7;.
MWP/]6S)?WA#'[V"!TX^^RJI+$>'_`!/@8[X#'8'&\NUH5G]7G+S2=.":6VY^
M9YU1IX/Q.X/S"2Y?[2R_,<O4NG-04L5"#_E;]K)IOXM43P:!`_Q<^.G@VZ58
M8?BE\._#>MV;-D0R16^GZQX)UQBF=SRQR3Z8\FP_*MQ#T+BHGC)QX:X1S.E[
MTN'<RQ5":6Z<JE''4%?9*2C54;[N,NB*IY?3?%O'63U;0AQ3E.#Q-.]^5QA2
MQ&6XEVW;C*5%RY=E*&SDC/T*WBUGP[\.;K45%I%K'P^U[X)>)$D&8]'\3*+*
MQ2*ZC*AA_P`3KPYJEBH9D!EO;5!DSH:WQ<Y8/'9Y2P[YY83,</GN%:T=;"OG
MJ-P>W\#$TJSLG:$*C=E!G/@:<<9EW#E7$KV,<9E.*X;QB>V'QB]G249JU_\`
M><)7H1NXWG4I15W4B?0WAG4GU'2;;[2@M]3LE6PUFS^ZUGJEJBQW<6W)/DN_
M[Z%^DD$\,JY60$_$X^@L/B9JF^;#U&ZE"?2=*;;@_P#$E[LU]FI&47JF?H>6
M8EXC"4_:+V>)H)4L13V=.O!)5(V_ED_?IRVG3E":NI)F_7&=X4`%`'#_`!.\
M,W?C3X;?$+P;I\T-O?\`BSP/XL\,V4]P";>"[U[0;_2K::<+SY*372,V.=JF
M@#X8_P""<WQA\+/\"O#WP(\47ECX+^,OP.EU;P'XW^'FO3P:1K]M)I^MW[V&
MK6>G7DJ2:A87-G<VRR7-N)$%TLRDA9(6E`/T0L]4TR_>ZBT[4;"]DLI%AO([
M.[M[E[25UWI%=)!(QMY&3Y@KA21R!B@#\G?A!\(/`FF?\%/_`([K::7(NG>#
M/`^G_%7PIH3W4KZ!X?\`B%\4;/PY8>-O%6E:2Q\BTU74;;SE>5%!'VI\<1P"
M``ZO]I;7K?X!?MS_```_:.\<H;+X/^)?AGKOP*\1>+VM))[#P1XANM7U;7]%
MOM:N8\_V=97TVI6T0N'`5(+34Y&)6%\`;>1^D4'C+PA<V%IJEKXJ\-SZ7?\`
MV<6&HP:YIDMA>&[\L6HM+R.Z,5QYQFB\ORW;?YJ;<[AD`^`O@]>V=E_P48_;
M+:\N[6S5OAU\"E0W-Q#;AB/#D!(3S77=@8SC.,C/44`>K_MP?%^]^'7[.OB9
M/`URE]\0?BA?:?\`!SX9VVFW4+7=UXS\?RMH\36$J.52]LM+DU.^C8G"RV<0
M8C<*`/B+Q9\(_P!K/5OV1(/V58/V0_!NG:%H7@_1]-TGQ38_M">'[G5K3Q/X
M>N;?75\96VDQ^&HC+J=YXB@N;Z2TCO(MYU&>`3!7W4`9?QI^(FO?'?\`8P_9
M5_:EL=/U#Q#J_P"SW\7O`7C;XP^'K!'_`+3$_@&^?1/'%VUKMWQ3C4[2QU#!
M&(++6)+B0B.)V4`_73P'\7OAE\3/">G>-O`_C?PWKWAK4[**^AU&SU:R(MHY
M45V@U*%IA)IE]"S>7-;72Q2PR*T<B*RD4`?FC^W!X1\)?%G]KG]A+PIKNL7\
M'A'Q39?&9YM:\*^)9-`O3;1>&]*U.RN=*\2Z=*&MHY;BVM_WD$G[Z-VC#8EH
M`^P?AI^SS\+O@9H/Q+N/A]XF\:Z[<^(_"=S#J<7BWXBZMXX2V@TRRU1[>2Q@
MU*ZE&GLTE[*))(P#(!&I/R"@#P3_`()3ZKI=G^Q3\.H;K4M/M95U_P"(;-%/
M>VT,B!O&VMD%HWE#)D8(R!D$'H1D`_2U65U5T961E#(RD,K*PRK*PX*D$$$4
M`.H`*`"@#Q'X\^&-4U?PA9>)?#5N;CQ;\-==T_Q[X=MD7,FH/HC.VJZ,H')%
M_H\E["$'+R^2/I]9P?C\/A,RJX#'3]GEN>X>IE^)D]%25=)4J_9>QK*$FWM'
MG9\5QUEF*Q>44<QRV'/FO#F)I9IA8+>J\,VZV'TNVJU!U(\J5Y34$4_$UP/%
M^@>`_C9\.HI-9U'PY`^N6>G6NT77B7P?KEM'%XK\+*I(`U;R88KBVB?[NHZ+
M#"0OF,1IE]/^R\9G'"F=R6$H8V2H3J2OR87&T).6$Q?_`%YYI.%62WPU><U>
MR3PS.?\`:N`R+C7AV#QF)RV+Q-.C"RGC,OQ,%''8&VWM^6*J482VQ>'A3:7-
M)IDIT-[.^\9:-!_PE'PJ^(D,.I>*K#3HIIKO0M4$<4!\7Z;96JBY/_'I;QZK
M:0*M[9W6FQWT*>?%=J:BL7"K2RO$R_L[B+(Y2I82I4<8PKTFW+ZE5G+]VOCE
M+"5)MT*]*K*A.7LY463+ZC[&OG."I_VIPKQ%&-;'4J,92J86O:,?[0HTH+VO
MV(QQU*"6)P]:C'$TX^UC73Z"Q%[Y5KJ]K+/XKL)+=!I?C7PE?6`UB[T]7)MK
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MQ5K2116XU^2WN=)\1&"`*((7\0Z#=6.I211*H$:-=$(!A0!0!TWPC^!?PE^`
MVC7WA_X1^"-*\$Z5JEW'?ZG!ITE_<S:C>Q0^1'=7]]JEY=75Y.L/R!YIG(!Q
MWH#;R-73/A/\/M&^)7B3XOZ;X<AM/B-XNT/3?#?B+Q,M[JCSZEHFD?9O[.L7
ML);YK&W6'[);8D@M8I&\H;W;G(!U'B3PQX<\8Z'J/AGQ9H6D>)?#NK0&UU30
M]=T^UU32K^W8AO*N["]BDAF4.JL-R':RJRX900`?+VB_L$?L@^'/%-CXRT7X
M&>%K#7]+U.VUG39H[SQ$^G:?JEG/'<VE[9:#-K3Z5:S17$44B&.R4*T2$#Y1
M@`T/BA^Q!^RW\9?&>I_$'XE_"BR\3>,=8BL(=2UJ3Q+XUTR6ZCTNPM],L5>U
MT7Q)9VJ>58VEO$"D"EA$"Q+$D@&YX4_9$_9U\#V?@/3O#'PVL]-L/ACXOU3Q
M[X'LWU[Q7?VVA>,-8MK*TOM?2'4]>N%O[XP:=9B'[:+E+9HB]LL3N[,`?2-`
M'F?P\^#OPV^$]OXML_A]X7M_#=CXY\3ZIXS\4:?!>ZI>:?J/B76UC35=22PU
M.^N8-/-U'#"CV]E';V^V&-1$%0``;'A?B']@/]CKQ/K<WB#5?@)X-34KBX>Z
MN1I#ZWX;TVYGDE,\CW.B>'=6L=-N`TQ+E9+1E+<XXH`ZSXD?L?\`[-WQ;TGP
M-H/C_P"%NDZSHWPTT:3P]X$TRWU7Q)H%GX:T26+3X6TVP@\.:U8+]E$.E:>B
MK*)-BVRA"H+;@`^$G[(/[.?P*U'7]6^%/PUM?".H>)]"F\-:[<0^(?%VJ&_T
M.XGBN9;!H]=\07L<*M/!$WF0K'(-N`X!((!Y,?\`@F;^P]_T0G3A[#QI\2E`
M_P"`CQD!^E`'VSHFC:9X<T72/#VBVHLM'T'2[#1M)LEDFF6TTS2[2*QL+59K
MB226416L$48>61W;9EF9B20#4H`*`"@`H`^<)H[CX!Z[JFK0P7%S\%O$VHS:
MKJ\%G!)<3?"[Q%?R[[_5XK6W0N?`NH2DS7*1(W]GW#O,JBWF<+]S!PXOP>'P
MTIQI\4Y?3C1HRG)0CFN&IJU.BYR:2Q]%>[2<FOK--*#;J1C?\ZG"IP)CL5BH
M0G4X-S*K*O7C"+E+)<75=ZE>,(J_]FUY>_6C%/ZK5;G%*G*2?7R^%]1TN]F\
M:_";4=)DMO$+C5];\)W5UCPEXLFN(E;^W-&U&RCG/A[Q!<QA"][;Q7%K>X1K
MJ`R_Z2OF1S"A7I0RGB*A6A4P*]CA\7"'^V8.,7_N]:E-P^L8>F[\M*<H5J&J
MI5%']T_6EE>(PE>>=<*8BA*EF#^L8G`SG_L&.E.-_K.'JTU/ZIBJBMS5J<:E
M#$:2KTG/]\N<EUCP-;WDMUKNF>+_`(0>(;FX4WTT<>H:5IFH7;AE:5M6T3[7
MX;UTLY+>=<,\Y$89U0`@=T<+F[I1IX.O@^),%3B_9Q;IU:M*"U25&O[+'8>R
MTY8)4TW:+EHSS98S(J5:53'8;'\(9A4G^\E%5:%&M4>CDZ^&]KEN)NW?GJ-U
M&ES2C&S1)=^(OA['"S7WQUU6]ME54-IIWB;P^MR5W#G_`(I;1H=1WY."\<BG
MG!(J:6!SKF4:/"%&A.]U.IA<3R)_]S=>5"W9.+3*K9CP]&#=?CJO6I))<E'&
MX13M?_J!P\,3>^CE&2>MKD^CZI(@N;+X1?#R[@:^D#7OC;QK::GH.DR-@[+R
MX;6#_P`)+XNE3,@1!#%$W`^VQ*^ZIQ.'C^[J<29U"2H+]W@,#.E7K1OO"*H?
M[!@T].9\TI+_`)\3:L:8/%2BJE'A'AZ=-UVO:9EF-.MA:#[5)_6/^%+'RCKR
MQY(P>WUB$7S'HUE=6W@S3-)LO%WC!=2U35]6CL+?4=6%CILNJZUJMQ^XTS2-
M-M%58H5=]D%K'Y[QQ1YEED*O*WAU:4\SKXBKEF6?5\/A:+J2I4?:5%1H4H^]
M5K59MMR:5ZE1\D93=H0BG&"^BHU:>38;"4,VSA8C%8NNJ4*U?V5%U\17G[E&
MA1II*,4WRTJ4>>48*\ZDVI3?95Y9[(4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`QXTE1XI422.1&CDC=0Z.C@JZ.C`AD9200000<&FFXM2BW&46
MFFG9IK5--;-='T%*,91<914HR3335TT]&FGHTUHT]SQ5_A;K'@^ZGU'X/>(+
M?PO;W,\EW>>`M<M9M3^'UY<3-OFDTZTMY8[SPA<2N69GTN0VQ8@M9.>OU4>(
M,+F5.%#B;!2Q\Z<5"&88><:68PBM(JI.2=+&1BM$L1%54M%7B?%2X7QF3U)U
M^#\PAE5.I)SJ97B82K954G)WDZ4(2C6P$Y-MREA9.DWJ\/(O0?$#QQI8\GQ9
M\(_$L<J@C[?X)U+1/%^DSLBJ2\4<EYINJ0*Y+86;31C`&XYS64LERFO[V6\2
M87E_Y]XZE7P5:-[Z-J%?#RMI=QK_`"1O#B#/,)[F;<(XR,H_\O<MK8;'T)-)
M7<8NIAL5!2ULIX;3:[(HOBO8!U6S^&7Q9:X8,`B_#K4-/Q@;F5[S4&M;9,L,
M`M<`$XP2.:J7#E:S]IGV3QIQMK_:5.IOII"DJE3STA=+ST)AQ7AU)*CPSGKJ
M.^BRBK2\VG4JNE26NFM1)O9VU*TOB7XS^)<0>&O`&E^`K.5<G7_B'K%IJ=_!
M&ZK\]MX1\)W5P)+E2S$)=ZM:KE!N!!Q5QP'"V7^]CLYJYO4A_P`P^6T)TJ;:
M;TEC,7"'+%Z7=+#5'9Z.YE+,N,\RM3RS(*.049+_`'K-L13K58II:PP&`G4O
M-7=E6Q=)77O*VAO>%?A?IVAZM_PE?B'5=1\<>.6AD@'BC7Q`O]F03_Z^R\,:
M+;(MCX8L'Z,EG'YT@XGGFZUQYAG];%8;^S<#AJ6491%J7U3#\W[V2^&>*KR;
MJXJHNCJRY(O^'3@=^5<,8?`XO^U<PQ=;.\\<7'Z[BN5>QC+XJ>"P\$J&"I/9
MQHQ]I-:5:M0]/KP#Z<*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
K*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c91699p9169902.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c91699p9169902.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`"T"00,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`\]^*NK:CH7P_\2ZII%U)8ZC:
M6D#6UU$$,D#2WUK"[('5E#&.1QG!QG(Y`-`'GWPU\1:I>>+O[,T[Q!JOBKPT
MWA.QU'5;W4R+E=)\22M'YEE:Z@+>+>KJSDP9?;SS^[-`;?(^@Z`,_5II+?2]
M2GA;9-!I]Y-$X`)22*WD=&`((.&4'!&.*`/EWP!XJ\3:A<_#V;3_`!5JWB/5
MM8NK]O&^B74L%W8Z5H\<\D<.H-'';H='8*$,8W_O68`#!P0-CZRH`*`/FSPA
MX@O=4^)OBG3=5\5^*D_LSQ9>VVBZ+:0O)H4UG"+MWMM1G2PD2VC41KL5YX2V
M``230!])T`%`'SOX%\27][X[U73?&'B37]*\30ZKJ:Z?X3FCAMO#E]HRQL+)
MK`FV)N9U0--O$RLX16&X%L`'T10`4`?._P`/O$M_?>-=5T[Q?XDU_3/%,.I:
MJMIX1N(X;7P]=Z2JN+-].!M<W$L<8,N]9@SA`PWKNP`?1%`!0`4`%`'F'QBU
MG5/#_P`/]9U/1KV73M0ADTV.&Z@">;$MQJ-K!-LWJP5FBD=<XR-V1@T`<W\.
M]7U:Z\7:KI^GZ]J/BOP;!H5A/)JVHRQ7OV'Q)(8S<:;:ZG%!&+G]P[.\7S>5
ME02".0/P/<Z`,O7)I;?1=8G@=HIH-+U":&1.&CEBM)GC=3V974$>XH`\5^!V
MM7&O:<+[4?%'BC6-8:Q?^T+#5('31;7-_(D$^G7/V&..XG,,2!MEQ)M\QP5'
M8`]^H`Y[Q;<W%EX5\27EI*]O=6F@ZO<VT\9"R03PV%Q)%*A(P'6158<=10!A
M_"_4;_5O`'A?4=3NIKV_NM.\VYNYR&FFD^T3KOD(`&[:JCIVH`[V@#A/B=J-
M]I'@'Q/J.F74MC?VFG&6UNH"%E@D\^%=Z$@@'#$=.]`&'\)+\:GH'VYO$/B3
M7;N>#36U`:_;R01V5\]FLMQ%I1DLK<36;22-^\1IE8(N']0/P/5Z`.=\6:Y'
MX9\,ZYKLA`&EZ;<W,:G^*X$96VC`[F2Y:),=]U`'FGP?UWQ'(_B#POXPOYK[
M7M*;2]6CFN"/-;3=<T^"ZCB7:J_)!-OCZ<%\=J`/;:`*]XUPEI=/:(LETEO.
MUK$YVI)<+$QA1CV5I`H)]#0!X1\(/$4^K7U[!XB\4>(6\9P)>#6/"6L10V=A
M:8O!Y=SI%LMJA\F.'RT.V4D><Q9<;6(![_0!%.2L$S*2K+%(5(Z@A"01[@T`
M?.WP-UZ\\0JUUJ_BKQ3JFL1PZAY^F7L+C04MDNXH8)X;O[`L<EX`R?(MRS#>
M^4P#@#\#Z.H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`.4\<>&F\7^%=7\-I>#3VU2&*);MH#
M<"#R[F"X+&$21[\^3MQO7[V>U`&WI5@NEZ98:<I1OL5G:VK2)&(A*UO!'"TO
ME@G:7\O.,GKC)Q0!H4`5+ZV^V6-Y9A_+-U:W%L)-N[9Y\+Q!]N1NV[LXR,XZ
MT`>.^&OA%-X4N?!^H:7KR1ZCH%K>:9K4HT]D@\1Z3=W4MTEM-"MW_H\T!E/E
MREI<%(SCY`*`/;:`"@#R?0/`/B'PWXJU[6K#Q/9#2/$>O2ZSJFD2Z)ON&1S,
M4MH-1-^/(*B;EQ"<X^Z,T!M\CUB@`H`\EB^'6M7OC'2O%/BGQ3'K$?AR6]DT
M&PM-%M]+,)O"=OVVXCGD:Y\I=@``&XQAB1E@P!ZU0`4`>2VWPZUF[\8Z9XK\
M5>*8]:_X1[[8-!LK31K?2?)%V7^:]GBGD-P8T8``!<E0Q(^8,`>M4`%`!0`4
M`<9X_P#";^-?"U_X<COETUKR2SD%VUN;D1_9;R"Z(\D2Q[MWE;?OC&[/.*`,
M[PQX%D\)^(]:U/3-35=$UV"VFN]`^R%([?68(TCFU.TG6?;$MP%=I(O*Y,GW
MOD44`>B4`4M2M#?Z=?V(D\HWME=6@E*[_+-Q!)")-F1NV[\XR,XQD4`<%\._
M!OB'P180:)>^)+/6-$LK66+3[2+1?[/N8)YKMKIYI;O[;,9DS+,`FQ?OCGY>
M0#TJ@#*US33K&BZOI"S"W.IZ9?:>LY3S!`;VUEMQ*8PR[POF;MNY<XQD9S0!
MR?P^\*:]X-TN+1-1U^TUC3+&VBM]*B@TC^S9K4+)-),9Y_MDWVG>9%Q\J;=I
MZYX`_`]!H`YGQCX>;Q5X8UGPZET+$ZK:&U%T83.(,R1R;S")$W_<QC>O7K0!
M4\%Z%X@\.Z9'I>M:[::U!96UC8Z4;721I;6MI96XMPDY%W-]ID9$B^?Y,;#P
M=W`!V-`'%^._"3^,]'M]#:_^P6+:KI]YJBB%I'O;"SE\^33T*S1^1YLBQYD^
M;&S[N3P`8>D_#*Q\.>-(/%'AZZ;3;%]'ETK4]&D^U7GVUFD\V"Z6]NKQWA:-
MDA&PJXPAQMW&@-O*QZA0!%,LCPRI#((96C=8IB@D$4C*0DAC)`<*Q#;21G&,
M\T`>7>'/AYJMGXN;QIXI\2IX@UF#2SH^GBTTB#1K:"T9F9I9XX9I#/<,))!U
M`'F'J`H4#;Y'JU`#)4\R.2/.W>CIG&<;E*YQ[9H`\N^'/@3Q#X#MTTF7Q-9:
MIH$7VR6*Q31/L=VMU=S++YIOOM\I:-3O&SRQG<.>*`V^1ZI0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`&7JVJQZ/:K=/9:G>J9DA$.E6$^H7*EU=
MM[06X++$-A!?H"RCO0!S?_"=6O\`T+GC7_PEM3_^-T`'_"=6O_0N>-?_``EM
M3_\`C=`!_P`)U:_]"YXU_P#"6U/_`.-T`'_"=6O_`$+GC7_PEM3_`/C=`!_P
MG5K_`-"YXU_\);4__C=`!_PG5K_T+GC7_P`);4__`(W0`?\`"=6O_0N>-?\`
MPEM3_P#C=`!_PG5K_P!"YXU_\);4_P#XW0`?\)U:_P#0N>-?_"6U/_XW0`?\
M)U:_]"YXU_\`"6U/_P"-T`'_``G5K_T+GC7_`,);4_\`XW0`?\)U:_\`0N>-
M?_"6U/\`^-T`'_"=6O\`T+GC7_PEM3_^-T`'_"=6O_0N>-?_``EM3_\`C=`!
M_P`)U:_]"YXU_P#"6U/_`.-T`'_"=6O_`$+GC7_PEM3_`/C=`!_PG5K_`-"Y
MXU_\);4__C=`!_PG5K_T+GC7_P`);4__`(W0`?\`"=6O_0N>-?\`PEM3_P#C
M=`!_PG5K_P!"YXU_\);4_P#XW0`?\)U:_P#0N>-?_"6U/_XW0`?\)U:_]"YX
MU_\`"6U/_P"-T`'_``G5K_T+GC7_`,);4_\`XW0`?\)U:_\`0N>-?_"6U/\`
M^-T`'_"=6O\`T+GC7_PEM3_^-T`'_"=6O_0N>-?_``EM3_\`C=`!_P`)U:_]
M"YXU_P#"6U/_`.-T`'_"=6O_`$+GC7_PEM3_`/C=`!_PG5K_`-"YXU_\);4_
M_C=`!_PG5K_T+GC7_P`);4__`(W0`?\`"=6O_0N>-?\`PEM3_P#C=`!_PG5K
M_P!"YXU_\);4_P#XW0`?\)U:_P#0N>-?_"6U/_XW0`?\)U:_]"YXU_\`"6U/
M_P"-T`'_``G5K_T+GC7_`,);4_\`XW0`?\)U:_\`0N>-?_"6U/\`^-T`'_"=
M6O\`T+GC7_PEM3_^-T`'_"=6O_0N>-?_``EM3_\`C=`!_P`)U:_]"YXU_P#"
M6U/_`.-T`'_"=6O_`$+GC7_PEM3_`/C=`!_PG5K_`-"YXU_\);4__C=`!_PG
M5K_T+GC7_P`);4__`(W0`?\`"=6O_0N>-?\`PEM3_P#C=`!_PG5K_P!"YXU_
M\);4_P#XW0`?\)U:_P#0N>-?_"6U/_XW0`?\)U:_]"YXU_\`"6U/_P"-T`'_
M``G5K_T+GC7_`,);4_\`XW0`?\)U:_\`0N>-?_"6U/\`^-T`'_"=6O\`T+GC
M7_PEM3_^-T`'_"=6O_0N>-?_``EM3_\`C=`!_P`)U:_]"YXU_P#"6U/_`.-T
M`'_"=6O_`$+GC7_PEM3_`/C=`!_PG5K_`-"YXU_\);4__C=`!_PG5K_T+GC7
M_P`);4__`(W0`?\`"=6O_0N>-?\`PEM3_P#C=`!_PG5K_P!"YXU_\);4_P#X
MW0`?\)U:_P#0N>-?_"6U/_XW0`?\)U:_]"YXU_\`"6U/_P"-T`'_``G5K_T+
MGC7_`,);4_\`XW0`?\)U:_\`0N>-?_"6U/\`^-T`'_"=6O\`T+GC7_PEM3_^
M-T`'_"=6O_0N>-?_``EM3_\`C=`!_P`)U:_]"YXU_P#"6U/_`.-T`'_"=6O_
M`$+GC7_PEM3_`/C=`!_PG5K_`-"YXU_\);4__C=`!_PG5K_T+GC7_P`);4__
M`(W0`?\`"=6O_0N>-?\`PEM3_P#C=`!_PG5K_P!"YXU_\);4_P#XW0`?\)U:
M_P#0N>-?_"6U/_XW0`?\)U:_]"YXU_\`"6U/_P"-T`7],\50:E>164>C>)K)
MI!(1/J6@WUA9IY<;2$27,R!(RP7"@GYF(`Y-`'4T`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
:`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
